MI2 COST-EFFECTIVENESS VS. COST-UTILITY ANALYSIS: DOES ADJUSTING FOR HEALTH-RELATED QUALITY OF LIFE REALLY MATTER?  by Tengs, TO & Lin, TH
124 Abstracts
therapy is used, between -$7.9 and $68.8 million in El
Salvador, and between -$888.8 thousand and $8.6
million in Belize. 
CONCLUSIONS: Since the ratio of antiretroviral drug
costs to GDP was 0.041% in Brazil in 2000, these three
Central American countries may have more difﬁculty
affording antiretroviral therapy unless double combina-
tion therapy is used.
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OBJECTIVE: An issue that has recently received atten-
tion from health economists is how to handle the problem
of missing data in stochastic cost-effectiveness analysis.
The purpose of this paper is to highlight the impact 
that different approaches to the imputation of missing
data can have on estimates of the physical quantities of
medical care resource use. 
METHODS: Medical care resource use data were 
collected prospectively in a 6-month RCT comparing 
two treatments for a chronic condition that is charac-
terised by acute episodes. Two approaches of the 
multiple imputation were used to address the problem of
missing data. Method A relied on imputing missing data
for total costs and then estimating the physical quantities
of medical care resource use. Method B relied on imput-
ing missing data for the physical quantities of medical
care resource use and then estimating total costs. Results
for physician and nurse visits and days in the hospital
were reported. 
RESULTS: The two multiple imputation approaches 
produced different estimates of medical care resource use.
For method A, the average number of physician and nurse
visits and days in the hospital between the two groups
were 5.7 vs. 5.3 physician visits, 1.0 vs. 0.9 nurse visits,
and 4.0 vs. 4.7 days in the hospital. For method B the
average number of physician and nurse visits and days 
in the hospital between the two groups were 6.0 vs. 6.3
physician visits, 1.2 vs. 1.3 nurse visits, and 4.0 vs. 5.0
days in the hospital. 
CONCLUSIONS: Medical care resource use estimates are
sensitive to the imputation approach. Method B builds
prediction models speciﬁcally for the utilisation compo-
nents under the imputation and results from the imputed
datasets are believed to be less biased. It also provides
more ﬂexibility for analysing the cost components.
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The US Public Health Service Panel on Cost-Effectiveness
issued a series of recommendations designed to improve
the rigor and consistency of cost-effectiveness analyses.
While the Panel’s individual recommendations are largely
sound, they nevertheless vary in importance. That is, the
violation of some recommendations will yield dramati-
cally different cost-effectiveness estimates and resource
allocation decisions than the violation of other 
recommendations. 
OBJECTIVE: The Panel has advocated the use of quality-
adjusted life-years (QALYs) as the best way to evaluate
outcomes in a cost-effectiveness analysis. We consider the
importance of this recommendation for cancer preven-
tion, screening, and treatment by studying the empirical
relationship between cost/life-year and cost/QALY. In
addition, we consider whether adjusting for health-
related quality of life (QOL) affects the ultimate resource
allocation decision implied by the cost-effectiveness ratio. 
METHODS: We identiﬁed 198 articles reporting two 
or more outcome measures for the same intervention:
cost/life-year, cost/QALY, total life-years, total QALYs,
incremental life-years, or incremental QALYs. We calcu-
lated a correlation matrix for these outcomes and per-
formed a regression analysis to examine the relationship
between cost/life-year and cost/QALY. We also employed
various willingness to pay (WTP) thresholds to assess
whether the use of cost/life-year would yield different
resource allocation decisions than cost/QALY. 
RESULTS: The correlation between the total life-years
and total QALYs associated with the intervention is 0.97
(P < 0.0001). The correlation between cost/life-year and
cost/QALY is 0.78 (P < 0.0001). Assuming a $50,000
WTP threshold, adjustment for QOL would affect choice
in 7% of cases. With a $400,000 threshold, QOL would
affect choice in 2% of cases. 
CONCLUSION: The outcome measures of life-years and
QALYs are highly correlated with one another. While
adjusting for QOL can make an important difference 
in some economic analyses, it generally does not affect
implied resource allocation decisions for cancer preven-
tion, screening, and treatment.
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